» Articles » PMID: 24460831

Assessment of Changes in Tumor Heterogeneity Following Neoadjuvant Chemotherapy in Primary Esophageal Cancer

Overview
Journal Dis Esophagus
Specialty Gastroenterology
Date 2014 Jan 28
PMID 24460831
Citations 53
Authors
Affiliations
Soon will be listed here.
Abstract

To assess the changes in computed tomography (CT) tumor heterogeneity following neoadjuvant chemotherapy in esophageal cancer. Thirty-one consecutive patients who received neoadjuvant chemotherapy for esophageal cancer were identified. Analysis of primary tumor heterogeneity (texture) was performed on staging and post-chemotherapy CT scans. Image texture parameters (mean grey-level intensity, entropy, uniformity, kurtosis, skewness, standard deviation of histogram) were derived for different levels of image filtration (0-2.5). Proportional changes in each parameter following treatment were obtained. Comparison between pathological tumor response and texture parameters was analyzed using Mann-Whitney U-test. The relationship between CT texture and overall survival) was estimated using the Kaplan-Meier method. Tumor texture became more homogeneous after treatment with a significant decrease in entropy and increase in uniformity (filter 1.0 and 2.5). Pretreatment (filter 1.5, P = 0.006) and posttreatment standard deviation of histogram (filter 1.0, P = 0.009) showed a borderline association with pathological tumor response. A proportional change in skewness <0.39 (filter 1.0) was associated with improved survival (median overall survival 36.1 vs. 11.1 months; P < 0.001). CT tumor heterogeneity decreased following neoadjuvant chemotherapy and has the potential to provide additional information in primary esophageal cancer.

Citing Articles

Nomogram based on multimodal magnetic resonance combined with B7-H3mRNA for preoperative lymph node prediction in esophagus cancer.

Xu Y, Lu P, Gao M, Wang R, Li Y, Guo R World J Clin Oncol. 2024; 15(3):419-433.

PMID: 38576593 PMC: 10989267. DOI: 10.5306/wjco.v15.i3.419.


CT-based pancreatic radiomics predicts secondary loss of response to infliximab in biologically naïve patients with Crohn's disease.

Yang T, Feng J, Yao R, Feng Q, Shen J Insights Imaging. 2024; 15(1):69.

PMID: 38472447 PMC: 10933237. DOI: 10.1186/s13244-024-01637-4.


Novel Advances in Qualitative Diagnostic Imaging for Decision Making in Multidisciplinary Treatment for Advanced Esophageal Cancer.

Okazumi S, Ohira G, Hayano K, Aoyagi T, Imanishi S, Matsubara H J Clin Med. 2024; 13(2).

PMID: 38276137 PMC: 10816440. DOI: 10.3390/jcm13020632.


Predicting response to CCRT for esophageal squamous carcinoma by a radiomics-clinical SHAP model.

Cheng X, Zhang Y, Zhu M, Sun R, Liu L, Li X BMC Med Imaging. 2023; 23(1):145.

PMID: 37779188 PMC: 10544369. DOI: 10.1186/s12880-023-01089-0.


Radiomics model based on contrast-enhanced CT texture features for pretreatment prediction of overall survival in esophageal neuroendocrine carcinoma.

Zhou Y, Song L, Xia J, Liu H, Xing J, Gao J Front Oncol. 2023; 13:1225180.

PMID: 37664013 PMC: 10473874. DOI: 10.3389/fonc.2023.1225180.